These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19242289)

  • 41. The answerable question and a hierarchy of evidence.
    Hamilton J
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):596-600. PubMed ID: 15908843
    [No Abstract]   [Full Text] [Related]  

  • 42. What is the significance of the new warnings about suicide risk with Strattera?
    Miller MC
    Harv Ment Health Lett; 2005 Dec; 22(6):8. PubMed ID: 16437773
    [No Abstract]   [Full Text] [Related]  

  • 43. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
    Guertin J; LeLorier J; Durand M; Gow R; Holbrook A; Levine M
    J Popul Ther Clin Pharmacol; 2014; 21(3):e357-69. PubMed ID: 25326915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologic mood destabilization: case vignettes.
    Swann AC
    CNS Spectr; 2009 Nov; 14(11 Suppl 11):9-11; discussion 12-4. PubMed ID: 20173695
    [No Abstract]   [Full Text] [Related]  

  • 47. Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.
    Kratochvil CJ; Faries D; Vaughan B; Perwien A; Busner J; Saylor K; Kaplan S; Buermeyer C; Swindle R
    J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):51-62. PubMed ID: 17343553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exposure to attention deficit hyperactivity disorder medications during pregnancy.
    Humphreys C; Garcia-Bournissen F; Ito S; Koren G
    Can Fam Physician; 2007 Jul; 53(7):1153-5. PubMed ID: 17872810
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ADHD update: new data on the risks of medication.
    Harv Ment Health Lett; 2006 Oct; 23(4):3-5. PubMed ID: 17183739
    [No Abstract]   [Full Text] [Related]  

  • 51. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The evidence-based pharmacological treatment of paediatric ADHD.
    Vaughan BS; March JS; Kratochvil CJ
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):27-39. PubMed ID: 21329553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attention deficit hyperactivity disorder in adults.
    Rösler M; Casas M; Konofal E; Buitelaar J
    World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atomoxetine-associated hemospermia: a case report.
    Raj YP
    J Clin Psychiatry; 2008 Jul; 69(7):1189. PubMed ID: 18687023
    [No Abstract]   [Full Text] [Related]  

  • 56. [Atomoxetine in ADHD: caution].
    Karila L
    Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
    [No Abstract]   [Full Text] [Related]  

  • 57. [Drugs for attention deficit hyperactivity disorder].
    Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
    Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
    Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
    Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.